Tim Herpin, Ph.D.Chief Business Officer at Caribou Biosciences
Tim joined Caribou from AstraZeneca where he served as Vice President and Head of Transactions. In this role, he managed a group of business development professionals involved in the negotiation and execution of transactions in multiple disease areas. Among other deals, he was involved with AstraZeneca’s collaboration with Merck around its PARP inhibitor, the divestment of its antibacterial business to Pfizer, and the acquisition of a majority stake in Acerta Pharma. Prior to that, he served as Vice President of Strategic Partnering and Business Development for Oncology. Before AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation, as well as transactions in multiple disease areas.
Tim received his undergraduate degree in Chemistry from the École Polytechnique in France, his Ph.D. in Chemistry from the University College London, UK, and an M.B.A. from the NYU Stern School of Business.